Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc vs Efavirenz on CD4/CD8 Ratio in HIV
NCT03178084Phase 3Completed
- Start
- Oct 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of maraviroc in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoint: Change From Baseline in CD4/CD8 ratio at 120 weeks. Started Oct 2014; status: completed.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03178084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178084.